Could Enrichment Cloud CV Signal For Weight-Loss Drugs?
FDA’s Robert Temple says the trend in risk indicators is the important element when interpreting data from high-risk patients for low-risk patients, after some advisory panel members question the relevance of data from older, sicker participants to the younger patients who take obesity products.
You may also be interested in...
Only a superiority trial could give certainty of CV safety for weight-loss medications prior to approval, FDA’s Robert Temple tells the Endocrinologic and Metabolic Drugs Advisory Committee.
In raising pre-market safety standards, FDA says that development time will not necessarily increase if a robust protocol is used.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.